Symptomatic benefit typically lasts 12–36 months; some participants report sustained improvement at 5-year follow-up, while others experience symptom recurrence 2–3 years after treatment. Cartilage degeneration is a progressive disease, so repeated injections (every 18–36 months) may be needed to maintain benefit, or progression eventually necessitates conventional joint replacement.
Hip osteoarthritis (OA) develops when protective cartilage lining the femoral head and acetabulum undergoes progressive degradation—triggered by mechanical wear, inflammation, prior injury, or metabolic dysfunction—exposing the underlying bone. Cartilage lesions enlarge, bone spurs form, and synovial fluid (joint lubricant) becomes inflamed. Pain, stiffness, and loss of range of motion ensue, eventually limiting walking and activities of daily living. Cell therapy in hip OA leverages placental MSCs, engineered chondrocytes, and exosomes to deliver anti-inflammatory and cartilage-regenerative signals directly into the joint. Intra-articular injection (into the joint space) positions cells to interact with damaged cartilage surfaces, synovial tissue, and local immune cells, potentially slowing degeneration or promoting cartilage matrix repair.
Am I a candidate? → · Hip Osteoarthritis: full overview → · Hip Osteoarthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită